[Chymotrypsin therapy in adhesion processes of the middle ear].
D001786:Blood Glucose / Q000032:analysis; D001798:Blood Proteins / Q000032:analysis; D002784:Cholesterol / Q000032:analysis / Q000097:blood; D002908:Chronic Disease; D002918:Chymotrypsin / Q000008:administration & dosage / Q000627:therapeutic use*; D004432:Ear, Middle / Q000032:analysis; D005688:Galactosamine / Q000097:blood; D005947:Glucose / Q000032:analysis; D006025:Glycosaminoglycans / Q000032:analysis / Q000097:blood; D006311:Hearing Disorders / Q000188:drug therapy; D006595:Hexosamines / Q000032:analysis / Q000097:blood; D006801:Humans; D006863:Hydrogen-Ion Concentration; D009093:Mucus / Q000032:analysis; D010033:Otitis Media / Q000188:drug therapy* / Q000378:metabolism; D011506:Proteins / Q000032:analysis; D014357:Trypsin / Q000008:administration & dosage; D014867:Water / Q000032:analysis
D001786:Blood Glucose; D001798:Blood Proteins; D006025:Glycosaminoglycans; D006595:Hexosamines; D011506:Proteins; D014867:Water; D005688:Galactosamine; D002784:Cholesterol; D002918:Chymotrypsin; D014357:Trypsin; D005947:Glucose
Die chymotrypsinbehandlung bei Adhäsivprozessen des Mittelohres.